{"disease":{"id":"immune-thrombocytopenia-itp","name":"immune thrombocytopenia itp"},"drugs":{"marketed":[{"drug_id":"rilzabrutinib","indication_name":"persistent or chronic immune thrombocytopenia (ITP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wayrilz","generic_name":"RILZABRUTINIB","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Wayrilz works by blocking a specific enzyme that helps platelet-destroying immune cells function."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07068425","title":"Longitudinal Observational Study on Immune Thrombocytopenia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07268898","title":"National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07070193","title":"Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06408324","title":"Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"European Research Consortium on ITP","has_results":false},{"nct_id":"NCT04968899","title":"IgIV Plus Prednisone vs High-dose Dexamethasone for ITP","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":272,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05029635","title":"Phase III Study on HMPL-523 for Treatment of ITP","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":272,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT05653349","title":"Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04518475","title":"Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":224,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06004856","title":"Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":195,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT05718856","title":"TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":166,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07421167","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":164,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07175493","title":"A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT07189910","title":"Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06371417","title":"Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT06723106","title":"Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT07196163","title":"An Exploratory Study of Golidocitinib in Adult Patients With ITP","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":138,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05338190","title":"Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07065968","title":"The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06992128","title":"Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":129,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07057778","title":"Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04915482","title":"TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":94,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02042560","title":"Study of Immune Thrombocytopenia Pathogenesis:","phase":"","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT06853444","title":"A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Shanghai Escugen Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT03951623","title":"The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT05885555","title":"A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06943937","title":"A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06962631","title":"V-IMMUNE® for Immune Thrombocytopenia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","has_results":false},{"nct_id":"NCT07400250","title":"Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07416032","title":"A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04346654","title":"A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01054443","title":"A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT06799611","title":"An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05086744","title":"Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06888960","title":"Safety Study of CC312 in Autoimmune Disease Patients","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"CytoCares Inc","has_results":false},{"nct_id":"NCT06973356","title":"Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia","phase":"NA","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT07019545","title":"A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT06880081","title":"Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Chongqing Peg-Bio Biopharm Co., Ltd.","has_results":false},{"nct_id":"NCT04669600","title":"A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":true},{"nct_id":"NCT07095127","title":"Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Nuvig Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03975361","title":"Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04812483","title":"Immunomodulation With Eltrombopag in ITP","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University Children's Hospital Basel","has_results":false},{"nct_id":"NCT04274452","title":"A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"argenx","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}